Research ExplorerPublicationsOncologic and Safety Outcomes for Retrograde and Antegrade E...

Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis

Standard

Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis. / Laukhtina, Ekaterina; Kawada, Tatsushi; Quhal, Fahad; Yanagisawa, Takafumi; Rajwa, Pawel; von Deimling, Markus; Pallauf, Maximilian; Bianchi, Alberto; Majdoub, Muhammad; Enikeev, Dmitry; Fajkovic, Harun; Teoh, Jeremy Yuen-Chun; Rouprêt, Morgan; Gontero, Paolo; Shariat, Shahrokh F.

In: EUR UROL FOCUS, Vol. 9, No. 2, 03.2023, p. 258-263.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Laukhtina, E, Kawada, T, Quhal, F, Yanagisawa, T, Rajwa, P, von Deimling, M, Pallauf, M, Bianchi, A, Majdoub, M, Enikeev, D, Fajkovic, H, Teoh, JY-C, Rouprêt, M, Gontero, P & Shariat, SF 2023, 'Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis', EUR UROL FOCUS, vol. 9, no. 2, pp. 258-263. https://doi.org/10.1016/j.euf.2022.11.014

APA

Laukhtina, E., Kawada, T., Quhal, F., Yanagisawa, T., Rajwa, P., von Deimling, M., Pallauf, M., Bianchi, A., Majdoub, M., Enikeev, D., Fajkovic, H., Teoh, J. Y-C., Rouprêt, M., Gontero, P., & Shariat, S. F. (2023). Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis. EUR UROL FOCUS, 9(2), 258-263. https://doi.org/10.1016/j.euf.2022.11.014

Vancouver

Laukhtina E, Kawada T, Quhal F, Yanagisawa T, Rajwa P, von Deimling M et al. Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis. EUR UROL FOCUS. 2023 Mar;9(2):258-263. https://doi.org/10.1016/j.euf.2022.11.014

Bibtex

@article{4bb9a4769a394434bc84bd3bb0b5504a,
title = "Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis",
abstract = "The aim of this study was to identify and summarize available data on oncologic and safety outcomes for retrograde versus antegrade endoscopic surgery in patients with upper tract urothelial carcinoma (UTUC). We systematically searched studies reporting on endoscopic surgery in patients with UTUC. The primary outcome of interest was oncologic control, including bladder and upper urinary tract recurrences. The secondary outcomes were any-grade and major complications. Twenty studies comprising 1091 patients were included in our analysis. The pooled bladder recurrence rate was 35% (95% confidence interval [CI] 28.0–42.3%; I2 = 48%) after retrograde endoscopic surgery and 17.7% (95% CI 6.5–32.1%; I2 = 29%) after antegrade endoscopic surgery. The pooled upper urinary tract recurrence rate was 56.4% (95% CI 41.2–70.9; I2 = 93%) after retrograde endoscopic surgery and 36.2% (95% CI 25.5–47.6%; I2 = 57%) after antegrade endoscopic surgery. The pooled complication rate was 12.5% (95% CI 0.8–32.8%; I2 = 94%) for any-grade complications and 6.6% (95% CI 0.1–19.1%; I2 = 89%) for major complications in the retrograde endoscopic cohort. In summary, our analyses suggest promising oncologic benefits of antegrade kidney-sparing surgery in terms of bladder and upper urinary tract recurrence rates in UTUC. Retrograde endoscopic surgery is a safe procedure with a minimal risk of complications and acceptable oncologic outcomes. Research should address the hypothesis that endoscopic antegrade surgery can be a safe and effective alternative for well-selected patients.Patient summaryOne of the surgical options for treatment of cancer of the upper urinary tract is removal of the tumor through a small telescope called an endoscope. The endoscope can be inserted via the urethra (called a retrograde approach) or through a small incision in the skin (antegrade approach). Our review shows that the antegrade approach seems to provide acceptable cancer control rates. Further research could help to identify the role for endoscope surgery in cancer of the upper urinary tract.",
author = "Ekaterina Laukhtina and Tatsushi Kawada and Fahad Quhal and Takafumi Yanagisawa and Pawel Rajwa and {von Deimling}, Markus and Maximilian Pallauf and Alberto Bianchi and Muhammad Majdoub and Dmitry Enikeev and Harun Fajkovic and Teoh, {Jeremy Yuen-Chun} and Morgan Roupr{\^e}t and Paolo Gontero and Shariat, {Shahrokh F}",
year = "2023",
month = mar,
doi = "10.1016/j.euf.2022.11.014",
language = "English",
volume = "9",
pages = "258--263",
journal = "EUR UROL FOCUS",
issn = "2405-4569",
publisher = "Elsevier BV",
number = "2",

}

RIS

TY - JOUR

T1 - Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis

AU - Laukhtina, Ekaterina

AU - Kawada, Tatsushi

AU - Quhal, Fahad

AU - Yanagisawa, Takafumi

AU - Rajwa, Pawel

AU - von Deimling, Markus

AU - Pallauf, Maximilian

AU - Bianchi, Alberto

AU - Majdoub, Muhammad

AU - Enikeev, Dmitry

AU - Fajkovic, Harun

AU - Teoh, Jeremy Yuen-Chun

AU - Rouprêt, Morgan

AU - Gontero, Paolo

AU - Shariat, Shahrokh F

PY - 2023/3

Y1 - 2023/3

N2 - The aim of this study was to identify and summarize available data on oncologic and safety outcomes for retrograde versus antegrade endoscopic surgery in patients with upper tract urothelial carcinoma (UTUC). We systematically searched studies reporting on endoscopic surgery in patients with UTUC. The primary outcome of interest was oncologic control, including bladder and upper urinary tract recurrences. The secondary outcomes were any-grade and major complications. Twenty studies comprising 1091 patients were included in our analysis. The pooled bladder recurrence rate was 35% (95% confidence interval [CI] 28.0–42.3%; I2 = 48%) after retrograde endoscopic surgery and 17.7% (95% CI 6.5–32.1%; I2 = 29%) after antegrade endoscopic surgery. The pooled upper urinary tract recurrence rate was 56.4% (95% CI 41.2–70.9; I2 = 93%) after retrograde endoscopic surgery and 36.2% (95% CI 25.5–47.6%; I2 = 57%) after antegrade endoscopic surgery. The pooled complication rate was 12.5% (95% CI 0.8–32.8%; I2 = 94%) for any-grade complications and 6.6% (95% CI 0.1–19.1%; I2 = 89%) for major complications in the retrograde endoscopic cohort. In summary, our analyses suggest promising oncologic benefits of antegrade kidney-sparing surgery in terms of bladder and upper urinary tract recurrence rates in UTUC. Retrograde endoscopic surgery is a safe procedure with a minimal risk of complications and acceptable oncologic outcomes. Research should address the hypothesis that endoscopic antegrade surgery can be a safe and effective alternative for well-selected patients.Patient summaryOne of the surgical options for treatment of cancer of the upper urinary tract is removal of the tumor through a small telescope called an endoscope. The endoscope can be inserted via the urethra (called a retrograde approach) or through a small incision in the skin (antegrade approach). Our review shows that the antegrade approach seems to provide acceptable cancer control rates. Further research could help to identify the role for endoscope surgery in cancer of the upper urinary tract.

AB - The aim of this study was to identify and summarize available data on oncologic and safety outcomes for retrograde versus antegrade endoscopic surgery in patients with upper tract urothelial carcinoma (UTUC). We systematically searched studies reporting on endoscopic surgery in patients with UTUC. The primary outcome of interest was oncologic control, including bladder and upper urinary tract recurrences. The secondary outcomes were any-grade and major complications. Twenty studies comprising 1091 patients were included in our analysis. The pooled bladder recurrence rate was 35% (95% confidence interval [CI] 28.0–42.3%; I2 = 48%) after retrograde endoscopic surgery and 17.7% (95% CI 6.5–32.1%; I2 = 29%) after antegrade endoscopic surgery. The pooled upper urinary tract recurrence rate was 56.4% (95% CI 41.2–70.9; I2 = 93%) after retrograde endoscopic surgery and 36.2% (95% CI 25.5–47.6%; I2 = 57%) after antegrade endoscopic surgery. The pooled complication rate was 12.5% (95% CI 0.8–32.8%; I2 = 94%) for any-grade complications and 6.6% (95% CI 0.1–19.1%; I2 = 89%) for major complications in the retrograde endoscopic cohort. In summary, our analyses suggest promising oncologic benefits of antegrade kidney-sparing surgery in terms of bladder and upper urinary tract recurrence rates in UTUC. Retrograde endoscopic surgery is a safe procedure with a minimal risk of complications and acceptable oncologic outcomes. Research should address the hypothesis that endoscopic antegrade surgery can be a safe and effective alternative for well-selected patients.Patient summaryOne of the surgical options for treatment of cancer of the upper urinary tract is removal of the tumor through a small telescope called an endoscope. The endoscope can be inserted via the urethra (called a retrograde approach) or through a small incision in the skin (antegrade approach). Our review shows that the antegrade approach seems to provide acceptable cancer control rates. Further research could help to identify the role for endoscope surgery in cancer of the upper urinary tract.

U2 - 10.1016/j.euf.2022.11.014

DO - 10.1016/j.euf.2022.11.014

M3 - SCORING: Review article

C2 - 36428210

VL - 9

SP - 258

EP - 263

JO - EUR UROL FOCUS

JF - EUR UROL FOCUS

SN - 2405-4569

IS - 2

ER -